| abstract |
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to formula (I) in which all radicals are defined in the present specification and claims. The compounds according to the invention are positive allosteric modulators of metabolic receptor-subtype 2 ("mGluR2"), which are used in the treatment or prevention of neurological and mental diseases associated with glutamate dysfunction and diseases involving the mGluR2 subtype of metabolic receptors. useful. In particular, the diseases are central nervous system diseases selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention also relates to pharmaceutical compositions and methods of preparing the compounds and compositions, the use of said compounds for the prevention or treatment of said diseases involving mGluR2. |